Skip to main content
. 2025 May 14;25(1):160. doi: 10.1007/s10238-025-01678-z

Table 2.

LncRNAs as diagnosis biomarkers in liver diseases

LncRNA Feature Cases Control Control condition Sensitivity
(%)
Specificity
(%)
AUC
HULC Up 90 77 HL 0.78
Linc00974 Up 150 150 pre- and postoperative 51.1 95.6 0.733
UCA1 Up 82 44 HL 92.7 82.1 0.861
Up 82 34 CHC 61 71 0.728
Up 34 44 HL 76.5 64.5 0.728
Up 70 38 HL 91.4 88.6 0.91
Up 70 32 CHC 71.4 87.5 0.838
Up 32 38 HL 68.8 67.4 0.76
WRAP53 Up 82 44 HL 85.4 82.1 0.896
Up 82 34 CHC 85.4 71 0.787
Up 34 44 HL 82.4 91 0.876
LINC01225 Up 66 70 HL 76.1 44.3 0.886
DANCR Up 52 43 HL/CHB/cirrhosis 83.8 72.7 0.868
Up 52 29 CHB 80.8 84.3 0.864
JPX Down 42 68 HL 100 52.4 0.814
MALAT1 Up 88 28 hepatic disease 51.1 89.3 0.66
SPRY4‑IT1 Up 145 63 HL 87.3 50 0.702
ENSG00000258332.1 Up 60 96 CHB 71.6 83.4 0.719
LINC00635 Up 60 96 CHB 76.2 77.7 0.75
LRB1 Up 326 73 HL 92.4 71.9 0.892
D16366 Down 58 85 HL 65.5 84.6 0.752
NONHSAT053785 Up 112 195 CHB and HL 73.2 74.4 0.801